ClinicalTrials.gg
RecruitingNCT05740033Updated Jun 12, 2025

Radial Forearm Donor Site Closure

An interventional study of Split-Thickness Skin Graft for Radial Forearm Donor Site Closure and Hatchet Flap for Radial Forearm Donor Site Closure in Oral Cancer, Oral Cavity Cancer and Donor Site Complication, sponsored by University of British Columbia. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by University of British Columbia · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Mouth Neoplasms with a site in Canada — 7 open to participants now, 9 under way, 1 of them phase 3. Mouth Neoplasms · Canada.

Planned enrollment
6th of 18
120 · median 40
Started
2023
with 1 other
No phase
7 of 23
4 open now
Registered
20th of 23
by date
Lead sponsor
3 of 23
University of British Columbia

Among the 23 studies in Mouth Neoplasms with a site in Canada, this one is the 6th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2023, is one of 7 with no phase, and was the 20th registered.

Mouth Neoplasms

447 studies on the registry are indexed under Mouth Neoplasms; 131 are open to participants now.

Browse Mouth Neoplasms studies →

Open to participants now

7 of the 23 studies in Mouth Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 97 Mouth Neoplasms studies recruiting now, 58 (60%) set no upper age limit and 23 (24%) stop at 75 or younger; 5 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Mouth Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

The radial forearm free flap (RFFF) is widely used in head and neck reconstruction. Its thinness, pliability, pedicle length, and vessel size are particularly suited for oropharyngeal and oral cavity reconstruction. Concerns about aesthetic and functional morbidity at the donor site have given rise to various techniques of closing the donor site, two of which are the split-thickness skin graft (STSG), taken from the thigh, and the hatchet flap, which uses a local flap within the radial forearm. This RCT will determine whether retrospectively reported improvements to aesthetic and functional outcomes for STSG patients are greater compared to hatchet flap patients.

Read the detailed description

The radial forearm free flap (RFFF), introduced by Yang et al. in 1981, is widely used in head and neck reconstruction. Its thinness, pliability, pedicle length, and vessel size are particularly suited for oropharyngeal and oral cavity reconstruction. Since the survival rate of the RFFF has reached more than 95%, the clinical focus has gradually shifted to the postoperative quality of life, particularly in terms of donor site morbidity.

Concerns about aesthetic and functional morbidity at the donor site have given rise to various techniques of closing the donor site of a RFFF. Many possibilities of donor site closures have been described, ranging from direct closure to skin grafting, tissue expansion, use of acellular dermal matrix and local flaps. Each of these techniques has its own advantages and drawbacks and the debate regarding the optimal method for closing the RFFF donor site continues.

Split-thickness skin graft (STSG) is a very thin strip of skin that is typically taken from the upper thigh and is the most commonly used method to cover the forearm after taking the RFFF. Advantages of this technique include reducing the amount of tension that is on the forearm which may lead to a better scar and better mobility while disadvantages include the need of an additional scar on the thigh and possible mismatch of the color of the skin graft when compared to the forearm.

Due to these potential limitations, surgeons have attempted to close the forearm directly by means of local flaps, which use nearby skin, soft tissue, and blood vessels to cover the forearm. The hatchet flap is a triangular local rotation flap, first described by Emmet in 1977, with a greater or lesser degree of advancement and with a back cut at the base of the flap through which it derives its vascular supply. This method may allow for quicker wound healing by primary intention and improved coverage of the tendons which should theoretically decrease donor site morbidity; however, since only tissue from the forearm is used this may lead to increased tension and therefore increased scar formation.

Risks and complications for both types of closure are the same which include bleeding, infection, hypertrophic scars, tendon exposure, divot formation, irregular skin graft surface, prolonged wound healing, and loss of skin graft. There are only a few studies on the functional and visual outcomes of forearm closure after RFFF removal using the hatchet flap or similar local flaps, warranting the need for further studies on these closure techniques.

It is hypothesized that donor site closure using the STSG flap will result in greater functional and aesthetic outcomes for the radial forearm donor site as measured by an improved scores to the 3 given questionnaires. Post-operative complication rates are also hypothesized to be lower for STSG flap closure when compared to hatchet flap closure.

The literature currently remains in a state of clinical equipoise, and at the study site (Vancouver General Hospital) the STSG and hatchet flap are the two most common methods of donor site closure. Based on a retrospective data analysis at the study site, functional and patient-reported scar aesthetic outcomes were improved for STSG flap closure patients when compared to hatchet flap patients. As a retrospective analysis, objective assessments of the scar could not be performed, nor could the immediate post-operative outcomes be taken and compared over a consistent post-operative time frame schedule. This study aims to address this knowledge gap by conducting a parallel-group randomized controlled trial for the study site's two common donor site closure techniques, STSG and hatchet flap.

03

Conditions studied

  • Oral Cancer
  • Oral Cavity Cancer
  • Donor Site Complication

Browse trials for

Keywords

  • Oral Cancer
  • Oral Cavity Cancer
  • Radial Forearm
  • Donor Site
  • Surgical Complications
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 or older
  • Oral cavity disease (malignant or benign) requiring radial forearm free flap reconstruction

Exclusion criteria

Exclusion Criteria:

  • Serious medical comorbidities including disease or other to surgery
  • Any pre-existing condition affecting the use of both hands, including previous major scars
  • Unable or unwilling to complete post-operative questionnaires in English
  • Pregnant or lactating women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    STSG arm

    Patient demographics will be recorded during the enrollment visit. During the participant's surgery in which the radial forearm free flap (RFFF) has been used, surgeons will perform a split-thickness thigh graft to close the forearm donor site. A photograph will be taken of the participants' forearm upon the removal of the dressing and splint. On each of the two follow-up clinic visits, another photo will be taken of the forearm scar and patient-reported outcome questionnaires will be provided for completion.

    Procedure: Split-Thickness Skin Graft for Radial Forearm Donor Site Closure

  • Active comparator
    Hatchet flap arm

    Patient demographics will be recorded during the enrollment visit. The hatchet flap closure of the forearm donor site will be performed following the RFFF's usage. A photograph will be taken of the participants' forearm upon the removal of the dressing and splint. On each of the two follow-up clinic visits, another photo will be taken of the forearm scar and patient-reported outcome questionnaires will be provided for completion.

    Procedure: Hatchet Flap for Radial Forearm Donor Site Closure

Interventions

  • ProcedureSplit-Thickness Skin Graft for Radial Forearm Donor Site Closure

    This method is performed by harvesting a 0.014-inch skin graft harvested from the anterolateral thigh on the side of the RFFF to reconstruct the forearm donor site. This skin graft is then used to cover the donor defect. The skin graft is sutured in place with 4-0 chromic suture, and a standard bolster dressing will be applied, and a partial splint will be left in place for five days post-operation.

  • ProcedureHatchet Flap for Radial Forearm Donor Site Closure

    The hatchet flap closures will be performed based on prior description by Lane et al. (12), except no drain is placed in situ. A back cut of 3 to 4 cm is made to aid closure (Figure 1). Tension will be minimized by maintaining the wrist in flexion. A mepore dressing will be applied to the donor site post-operatively for two days.

06

What researchers measure

Primary outcomes

  1. First Michigan Hand Outcomes Questionnaire (MHOQ) Measure

    A questionnaire that measures symptoms, function, aesthetics, and patient satisfaction in regards to the function of their hands. Responses are recorded on a 5-point Likert scale ranging from very good (1) to very poor (5).

    Time frame: Measure documented at 1 month post-surgery.

  2. Second MHOQ Measure

    A questionnaire that measures symptoms, function, aesthetics, and patient satisfaction in regards to the function of their hands. Responses are recorded on a 5-point Likert scale ranging from very good (1) to very poor (5).

    Time frame: Measure documented between 3-6 months post-surgery.

  3. First Patient and Observer Scale Assessment Scale (POSAS) Measure

    A questionnaire measuring both the patient's aesthetic perception and the trial coordinator's aesthetic and physical assessment of the scar formation along the donor site wound. Responses to questions are measured on a 10-point Likert scale ranging from the worst scarring imaginable (10) to the best scar imaginable (feels like normal skin, not scar tissue; 1).

    Time frame: Measure documented at 1 month post-surgery.

  4. Second POSAS Measure

    A questionnaire measuring both the patient's aesthetic perception and the trial coordinator's aesthetic and physical assessment of the scar formation along the donor site wound. Responses to questions are measured on a 10-point Likert scale ranging from the worst scarring imaginable (10) to the best scar imaginable (feels like normal skin, not scar tissue; 1).

    Time frame: Measure documented between 3-6 months post-surgery.

  5. First Decision Regret Scale (DRS) Measure

    A questionnaire measuring a patient's decisional regret related to receiving the surgery. Responses are measured on a 5-point Likert scale, ranging from extreme decisional regret (5) to no decisional regret (1).

    Time frame: Measure documented at 1 month post-surgery.

  6. Second DRS Measure

    A questionnaire measuring a patient's decisional regret related to receiving the surgery. Responses are measured on a 5-point Likert scale, ranging from extreme decisional regret (5) to no decisional regret (1).

    Time frame: Measure documented between 3-6 months post-surgery.

Secondary outcomes

  1. Localized Hematoma at Donor Site

    A severe pooling of blood at the donor site.

    Time frame: Patients will be monitored for 6 months post-operatively.

  2. Donor Site Infection

    Infection at the donor site or anywhere along the forearm scar.

    Time frame: Patients will be monitored for 6 months post-operatively.

  3. Donor Site Wound Dehiscence

    A re-opening of the donor site wound.

    Time frame: Patients will be monitored for 6 months post-operatively.

  4. Donor Site Tendon Exposure

    Exposure of the forearm tendons at the donor site.

    Time frame: Patients will be monitored for 6 months post-operatively.

  5. Donor Site Skin Necrosis

    Significant amount of dead or dying skin tissue overlying or abutting the donor site and scar.

    Time frame: Patients will be monitored for 6 months post-operatively.

  6. Donor Site Contractures

    A persistent tightening or contraction of skin, ligaments, tendons, or muscles at the forearm donor site.

    Time frame: Patients will be monitored for 6 months post-operatively.

  7. Keloid Scarring at Donor Site Wound

    Excessive scar tissue formation along the donor site wound.

    Time frame: Patients will be monitored for 6 months post-operatively.

  8. Divot Formation into Skin at Donor Site

    Visible and persistent depressions into the skin surface of the forearm.

    Time frame: Patients will be monitored for 6 months post-operatively.

  9. Skin Graft Irregularities at Donor Site

    Additional irregularities such as bumps, roughness, or changes to colour will be recorded.

    Time frame: Patients will be monitored for 6 months post-operatively.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2025, 34 months after the start.

Of 98 non-industry interventional studies with no phase under Mouth Neoplasms, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 97. This study's planned 34 months is above that.

Counting every sponsor, half of 99 studies reached it within 30 months; a quarter within 17 and three quarters within 107.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2023
First posted
Feb 22, 2023
StartActual
Feb 1, 2023
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05740033
Responsible party
Eitan Prisman (Clinical Associate Professor, University of British Columbia) — Principal investigator
First posted
Feb 22, 2023
Start date
Feb 1, 2023
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jun 12, 2025

Study contacts

Eitan Prisman, MD, FRCSC
Contact
eitan.prisman@ubc.ca
6048754126
Tayo Steininger
Contact
tstein12@student.ubc.ca
6048754111 ext. 22935

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion